Somatuline Depot (Lanreotide Acetate) Patent Expiration, LOE Window & CMS Spending

Somatuline Depot (Lanreotide Acetate) by Ipsen Biotech Sas: Off-Patent Genericized (AB Competition), 1 AB generics, $90.9M 2024 CMS Part D & Medicaid spend, and $9,460 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIpsen Biotech Sas
FDA Application & PathwayN022074 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$90.9M
2024 Medicare Part D Spend$57.7M
2024 Medicaid Spend$33.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,460 intro WAC)